Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07091734 · ClinicalTrials.gov registry record · Phase 2
Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
A Phase 2 study of Lipodystrophy, Partial, sponsored by University of Michigan.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT07091734 is a Phase 2 study of Lipodystrophy, Partial that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 32 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07091734, a Phase 2 study of Lipodystrophy, Partial, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to see if the clinical use of Tirzepatide in patients with lipodystrophy (a rare disorder associated with abnormal loss of the body's fat tissue) may lead to improved diabetes mellitus control and lowering of participant's triglycerides through the reduction of caloric intake. Study Hypothesis: \- The clinical use of Tirzepatide in patients with lipodystrophy may lead to favorable outcomes through the reduction of caloric intake.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Usual care medications
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-09-08 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07091734
The ClinicalTrials.gov registry entry for NCT07091734 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lipodystrophy, Partial appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT07091734 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07091734 about?
NCT07091734 is a clinical study titled "Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024". This study aims to see if the clinical use of Tirzepatide in patients with lipodystrophy (a rare disorder associated with abnormal loss of the body's fat tissue) may lead to improved diabetes mellitus control and lowering of participant's triglycerides through the reduction of caloric intake. Study...
What is the current status of trial NCT07091734?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-09-08. Estimated completion is 2029-09.
What conditions does trial NCT07091734 study?
This clinical trial studies the following conditions: Lipodystrophy, Partial.
What interventions are being tested in trial NCT07091734?
The interventions under investigation include: Tirzepatide (DRUG), Usual care medications (DRUG).
Who is sponsoring clinical trial NCT07091734?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07091734 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.